Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors

Author:

Schneider Gisbert,Geppert Tim1,Hartenfeller Markus1,Reisen Felix1,Klenner Alexander1,Reutlinger Michael1,Hähnke Volker1,Hiss Jan A1,Zettl Heiko1,Keppner Sarah2,Spänkuch Birgit2,Schneider Petra1

Affiliation:

1. Swiss Federal Institute of Technology, Department of Chemistry & Applied Biosciences, 8093 Zürich, Switzerland

2. Goethe-University, Department of Gynecology & Obstetrics, 60590 Frankfurt, Germany

Abstract

Background: De novo design of drug-like compounds with a desired pharmacological activity profile has become feasible through innovative computer algorithms. Fragment-based design and simulated chemical reactions allow for the rapid generation of candidate compounds as blueprints for organic synthesis. Methods: We used a combination of complementary virtual-screening tools for the analysis of de novo designed compounds that were generated with the aim to inhibit inactive polo-like kinase 1 (Plk1), a target for the development of cancer therapeutics. A homology model of the inactive state of Plk1 was constructed and the nucleotide binding pocket conformations in the DFG-in and DFG-out state were compared. The de novo-designed compounds were analyzed using pharmacophore matching, structure–activity landscape analysis, and automated ligand docking. One compound was synthesized and tested in vitro. Results: The majority of the designed compounds possess a generic architecture present in known kinase inhibitors. Predictions favor kinases as targets of these compounds but also suggest potential off-target effects. Several bioisosteric replacements were suggested, and de novo designed compounds were assessed by automated docking for potential binding preference toward the inactive (type II inhibitors) over the active conformation (type I inhibitors) of the kinase ATP binding site. One selected compound was successfully synthesized as suggested by the software. The de novo-designed compound exhibited inhibitory activity against inactive Plk1 in vitro, but did not show significant inhibition of active Plk1 and 38 other kinases tested. Conclusions: Computer-based de novo design of screening candidates in combination with ligand- and receptor-based virtual screening generates motivated suggestions for focused library design in hit and lead discovery. Attractive, synthetically accessible compounds can be obtained together with predicted on- and off-target profiles and desired activities.

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. İLAÇ TASARIMINDA YAPAY ZEKÂ UYGULAMALARI;Ankara Universitesi Eczacilik Fakultesi Dergisi;2023-11-19

2. Machine Learning in Drug Design;The Handbook of Medicinal Chemistry;2023-02-03

3. Artificial Intelligence in De novo Drug Design: Are We Still There?;Current Topics in Medicinal Chemistry;2022-11

4. Scaffold-Retained Structure Generator to Exhaustively Create Molecules in an Arbitrary Chemical Space;Journal of Chemical Information and Modeling;2022-02-21

5. Can Generative-Model-Based Drug Design Become a New Normal in Drug Discovery?;Journal of Medicinal Chemistry;2021-12-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3